Cullinan Therapeutics (CGEM) Interest & Investment Income (2020 - 2026)

Cullinan Therapeutics' Interest & Investment Income history runs 7 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income fell 37.72% year-over-year to $4.1 million in Q1 2026; TTM through Mar 2026 was $19.7 million, a 35.41% decrease from a year earlier, with the FY2025 full-year figure at $22.2 million, down 25.11% from the prior year.
• Interest & Investment Income declined to $4.1 million in Q1 2026 per CGEM's latest filing, from $4.6 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $8.4 million in Q3 2024 and bottomed at $197000.0 in Q1 2022.
• The 5-year median for Interest & Investment Income is $5.3 million (2023), against an average of $5.0 million.
• Across the five-year window, Interest & Investment Income jumped 2355.47% in 2022 and sank 39.25% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at $3.4 million in 2022, then soared by 75.89% to $5.9 million in 2023, then rose by 26.96% to $7.5 million in 2024, then sank by 38.56% to $4.6 million in 2025, then retreated by 11.2% to $4.1 million in 2026.
• Per Business Quant, the three latest CGEM Interest & Investment Income figures stand at $4.1 million (Q1 2026), $4.6 million (Q4 2025), and $5.1 million (Q3 2025).